Announcements & Events

TranScrip leading 'Navigating the New Drug Development Paradigm' at Genesis 2011
16th November 2011
Dr. Flic Gabbay, Founder Partner is leading a panel discussion at Genesis 2011 in London, 1st Dec 2011. Speakers from biotech, pharma and the support sector will address emerging problems and offer pathways to ensure companies continue to get the financial, knowledge and research support they need, to be successful. There are spaces left for delegates. Entry and programme details can be seen on the Genesis website, http://www.onenucleus.com/onenucleus-events?id=552. Any comments or suggestions can be addressed to flic.gabbay@transcrip-partners.com

Accelerated growth drives TranScrip into new areas
19th October 2011
In September/October, TranScrip welcomed 4 new Partners and Senior Partners: .................................................................................................................... Nigel Pluck, MA DPhil BM BCh (Senior Partner) augments our infectious disease group with his antiviral development knowledge. He led the global registration of pegylated interferon in hepatitis B and worked in hepatitis C and CMV as well as in antifungals, antibacterials and anti-inflammatories ........................................................................................................... Daniela Dastros-Pitei, MD, PhD (Senior Partner) adds yet another dimension in immunology & inflammation, latterly as Vice President & EU Head Clinical Development, Global Head of Inflammation/Biologics, at Eisai and led programmes from Phase I to Phase III, NDA/MAA filings, in inflammatory diseases, CVS, GI, urology, CNS, dermatology and metabolic diseases ..................................................................................................................... Helen Spain, BSc BTec (Senior Partner) adds significant depth to our regulatory group with over 21 years drug development experience, including 13 years within global regulatory affairs at Pfizer where she led complex regulatory submissions and rapid response activities globally, including in CNS, anti-infectives, ophthalmology, A & R, GUGI and PVD therapeutic areas ............................................................................................................................... Louise Whitley, MSc (Partner) Experienced in many aspects of Medical Writing, Pharmacovigilance and Medical Information. Ex-Senior Staff Editor BNF, an expert in preparation of common technical documents, SPC texts and clinical expert reports for product licence submissions and variations

On top of the World
18th August 2011
Sarah Daniels conquered Mount Kilimanjaro at 8.00hrs on 11/08/11.This is the highest mountain in Africa and the worlds 4th highest summit. The oxygen level at the summit is less than half of that at sea level, so this one of the hardest mental and physical challenges. Never-the-less, eight out of the group of 10 made it to the summit, after 5 days climbing. Sarah has so far raised £3317.00 (£4019.50 including gift aid) for her chosen charity ‘Motec Life-UK’ all of which will be used for the NUWLIFE programme for the malnourished in Northern Ghana. For further details please go to www.moteclife.co.uk.

And yet another partner joins TranScrip - Professor Tim Higenbottam
16th August 2011
Tim Higenbottam brings over 25 years of experience in Academic Respiratory Medicine and Pharmaceutical Medicine. Tim was Professor of Medicine in Sheffield before joining AstraZeneca R&D, where he led the process to link the selection of molecular targets for new therapies to major unmet needs in COPD and Asthma and development of outcome measures and study design for PoC. He joined Chiesi Farmaceutici as Corporate Director for Clinical Development, accountable for some 36 human studies per year for approval of Respiratory Therapies, across all Phases. He created strong Statistic/Data-Management and Clinical Pharmacology departments to support this work. In addition to his work at TranScrip, he is supporting two projects in the Innovative Medicine Initiatives (EU and Pharmaceutical Industry Joint Undertaking) and is the chairman of the Professional Standards Committee of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.

Another partner joins TranScrip - Dr. John Hutchison
16th July 2011
TranScrip is delighted to announce another major new appointments, John Hutchison as a Senior Partner. John is a pharmaceutical physician with a CNS specialism and was CMO and an Executive Board Member at Vernalis for 10 years, overseeing the Company’s development portfolio of CNS, pain and anti-obesity products, gaining the successful approval of the migraine treatment Frova, and actively involved with fundraising and M&A activities, restructuring the portfolio and R&D group during three corporate acquisitions. Latterly, John was CMO and head of R&D at Renovo, specialising in wound healing and scarring therapies, before joining TranScrip.

URGENT NEED Initiative - New leading antibacterial publications (see articles below)
16th August 2011

BSAC Standing Committee on Antibacterial Drug Discovery and Development
21st June 2011
Dr. Richard Bax and Dr. Tony White, 2 of TranScrip’s partners now sit on this important strategy group of the British Society for Antimicrobial Chemotherapy, with a remit to address the difficult problems in developing new and increasingly necessary antimicrobials.

Another TranScrip expansion - Tony White adds microbiology expertise
8th July 2011
An eminent microbiologist has joined the infectious disease team. Tony White has 35 years experience in antibacterial microbiology, development, and scientific communications in Beecham / SmithKline Beecham / GlaxoSmithKline and as an independent consultant. A genuine leader in the space; past trustee and member of Council of BSAC and core member of the BSAC Surveillance Working Party. Member of BSAC Working Group `The Urgent Need` for new antibacterials. • Participation on working groups of ESCMID, EFPIA, EU, IFPMA and WHO on antibacterial development and use. Past Joint Chair of EFPIA working group on antibacterial resistance and participant in ReACT consortium for sustainable antibacterial development and use. Expert reviewer for EU framework proposals • Author/presenter of publications and presentations on antibacterial properties, surveillance, development and use in/at international journals and conferences

TranScrip speaking at Microbes 2011 in Beijing (30th July to 1st August)

Confirmed TranScrip Attendances at conferences in 2011
22nd December 2011
TranScrip will be exhibiting at DIA Europe (Geneva, March 2011), at BioTrinity (Newbury UK, April 2011) and Genesis (London, Dec 2011). TranScrip will also have conferencing suites at ICAAC (Chicago, September 2011) and ECCMID (Milan, May 2011). Individual Partners will be at BIO-Europe (Milan, March 2011), Superdrugs & Superbugs (London, March 2011), European Federation of IASP Chapters (Hamburg, September 2011) and American Thoracic Society (Denver, May 2011) If you wish to meet us, connect with paul.branthwaite@transcrip-partners.com

Articles

Various
URGENT NEED Initiative - New leading antibacterial publications

16the August 2011
1. Link to the Urgent Need initiative and 4 relevant papers: http://www.bsac.org.uk/News/TUN 2. Link to current JAC journal: http://jac.oxfordjournals.org/content/current 3. Link to: http://jac.oxfordjournals.org/content/early/2011/06/22/jac.dkr260.full.pdf+htm

Pharma Magazine On-line
Heads in the ‘Cloud’? Is our world turning upside down?

6th June 2011
A new paradigm emerging for pharma http://www.pharma-mag.com/News/tabid/63/EntryId/306/Heads-in-the-Cloud-Is-Our-World-Turning-Upside-Down.aspx read more

Chemistry & Industry
A Risky Business

September 2010
Even after they are approved, drugs that make it onto the marketplace can never be guaranteed to be 100% safe, writes Sarah Daniels.....read more

Drug Discovery Today
The shrinking of the knowledge base – what is the impact of this on the speed and security of drug development?

November 09
We have all seen the litany of redundancy as blockbusters go generic and mainstream pharma reduces its cost base and/or merges with other struggling groups to compensate and/or restructures to move into new therapeutic areas of strategic importance. Not all announcements in the last few years... read more

Scrip News
TranScrip Partners fills pharma's skills gap

February 2009
The recent exodus of top level personnel from the pharmaceutical industry has left some companies struggling to fill the skills gap. Seasoned executives Paul Branthwaite and Dr Felicity (Flic) Gabbay explained to Scrip how their novel resourcing model TranScrip Partners could help...

Drug Discovery World
Living in Hard Times

Winter 2008/2009
Maintaining knowledge and experience internally is a challenge in today’s financial climate, in SME’s and in big pharma. Paul Branthwaite explains. read more

Pharmaceutical Technology Europe
Business Talk - Partnership Power

December 2008
TranScrip Partners provides pharma and biotech companies with strategic expertise on an “as needed” basis. Senior Partner Flic Gabbay explains why this approach is flourishing. read more

SP²
A new flexible model in resourcing expertise

November 2008
TranScrip Partners is responding to demand for flexible, specialist drug development and related support services within the pharmaceutical sector through the provision of expertise in a wide range areas. read more

Pharmaceutical Executive Europe
Instant Pharma

October 2008
In pharma’s changing employment landscape, companies that are downsizing still need to ensure they have affordable and reliable access to the right skills at the right time. read more

In-Pharma-Technologist
Group Offers ‘Pharma Leadership on Demand’

20th October 2008
A UK company has been launched with the aim of providing high lebel management expertise to pharmaceutical companies on an “on-demand” basis. read more

Transcrip in the News

OutSourcing-Pharma.com
Interview with Paul Branthwaite

9th September 2009
Listen to the audio interview with Paul Branthwaite discussing solution for contract R&D - click here.

Pharma
Phico Awarded £1 Million for Trials

6th February 2009
Phico Therapeutics has been granted a Wellcome Trust Strategic Translational Award totalling £1.03 million to cover Phase 1 and 2 trials of its lead candidate SASPject PT1.2. read more